双免疫联合对比单免疫治疗晚期NSCLC的长期生存:系统综述与重建个体数据Meta分析
该系统综述与重建个体数据Meta分析纳入6项随机III期试验、2881例晚期NSCLC患者,比较CTLA-4联合PD-L1/PD-1双免疫治疗与单免疫治疗。总体人群的中位总生存无显著差异,但在PD-L1 TPS<1%和STK11突变患者中双免疫治疗显著改善总生存。
核心结论
- 在晚期NSCLC总体人群中,双免疫治疗与单免疫治疗的中位总生存无显著差异。
- 在PD-L1 TPS<1%和STK11突变患者中,双免疫治疗与更长的总生存显著相关。
- 按肿瘤组织学或KRAS突变状态分层,两组总生存无显著差异。
研究设计与样本
- 系统综述与重建个体数据Meta分析,检索PubMed、MEDLINE和Embase至2024年11月21日。
- 纳入6项随机III期试验,共2881例可分析患者,其中双免疫治疗1282例、单免疫治疗1599例。
- 从Kaplan-Meier曲线提取个体数据,采用IPDfromKM方法重建,主要终点为5年总生存。
- 研究注册于PROSPERO,CRD420251081707。
主要发现
- 按肿瘤组织学(鳞癌 vs 非鳞癌)或KRAS突变状态分层,两组总生存无显著差异。
临床怎么用
- 对于晚期NSCLC且PD-L1 TPS<1%的患者,可考虑CTLA-4联合PD-L1/PD-1双免疫治疗以改善长期生存。
- 对于STK11突变患者,双免疫治疗可能带来总生存获益,治疗决策时可参考该生物标志物。
- 总体人群或KRAS突变、组织学分层未见显著获益,双免疫治疗的选择应结合生物标志物个体化评估。
局限性
- 个体数据从Kaplan-Meier曲线重建而非原始个体数据,可能存在提取误差。
- 仅纳入报告5年生存数据或特定生物标志物分析的随机III期试验,存在选择偏倚。
- 结果需在前瞻性临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors targeting PD-L1 or PD-1 as monotherapy or combined with CTLA-4 inhibitors or chemotherapy (or both) are the standard of care for patients with advanced non-small-cell lung cancer (NSCLC). However, it remains unclear which patients benefit from the addition of CTLA-4 inhibitors. We aimed to evaluate whether dual checkpoint blockade with CTLA-4 and PD-L1 or PD-1 inhibitors provides similar efficacy to PD-L1 or PD-1 inhibitor monotherapy, or whether these strategies produce distinct outcomes across NSCLC subpopulations. METHODS: We conducted a search of PubMed, MEDLINE, and Embase for randomised phase 3 trials published from database inception to Nov 21, 2024, that investigated PD-L1 or PD-1 inhibitors, with or without CTLA-4 inhibitors, in patients with advanced NSCLC. We focused on studies reporting Kaplan-Meier survival data at 5 years or biomarker analyses based on PD-L1, KRAS, and STK11 mutational status. Individual patient data were extracted from Kaplan-Meier curves with WebPlotDigitizer version 5 and reconstructed with the IPDfromKM method. The primary endpoint of the study was 5-year overall survival in the overall population and in subpopulations based on PD-L1 tumour proportion score (TPS), tumour histology, and mutational status (mutant vs wild-type) of KRAS and STK11. This study was registered with PROSPERO, CRD420251081707. FINDINGS: The initial search yielded 1026 results, and six randomised clinical trials met the eligibility criteria and were included. Among the 2881 patients eligible for analysis (838 [29·1%] female and 2043 [70·9%] male), 1282 received dual CTLA-4 and PD-L1 or PD-1 blockade and 1599 received single PD-L1 or PD-1 blockade. Patients treated with dual CTLA-4 and PD-L1 or PD-1 blockade had similar median overall survival compared with those treated with single PD-L1 or PD-1 inhibition (16·1 months [95% CI 15·0-17·8] vs 16·9 months [15·5-18·3]; HR 0·95 [95% CI 0·87-1·03], p=0·19). Median overall survival was significantly longer with dual CTLA-4 and PD-L1 or PD-1 blockade among patients with PD-L1 TPS less than 1% versus those treated with single PD-L1 or PD-1 inhibition (15·5 months [95% CI 13·6-18·5] vs 14·5 months [13·4-15·9]; HR 0·85 [95% CI 0·74-0·98], p=0·021), with 5-year overall survival rates of 16·6% (95% CI 13·4-20·6) versus 9·3% (7·0-12·3), respectively. Median overall survival in patients with tumours harbouring STK11 mutations was also significantly longer with dual CTLA-4 and PD-L1 or PD-1 blockade compared with single PD-L1 or PD-1 inhibition (13·9 months [95% CI 9·8-20·8] vs 7·8 months [6·4-12·9]; HR 0·67 [95% CI 0·49-0·91], p=0·012). However, no significant differences in overall survival were found between treatment groups by tumour histology (squamous vs non-squamous NSCLC) or by KRAS mutational status. INTERPRETATION: Compared with single PD-L1 or PD-1 inhibition, dual immune checkpoint blockade with CTLA-4 and PD-L1 or PD-1 inhibitors was associated with improved overall survival in patients with advanced NSCLC and PD-L1 TPS less than 1% and in those with STK11 mutations, but not in the overall population. Prospective validation of these results in clinical trials is warranted. FUNDING: NextGenerationUE.
引用
- Di Federico A, Stumpo S, Mantuano F, et al. Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis. Lancet Oncol. 2025. PMID: 41038207. doi:10.1016/S1470-2045(25)00429-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。